Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Percutaneous coronary intervention for stable angina in ORBITA

The ORBITA trial1 by Rasha Al-Lamee and coworkers has several issues that affect its validity. In ORBITA, 57 (29%) of patients had a fractional flow reserve (FFR) more than 0·80 and 64 (32%) had an instantaneous flow ratio more than 0·89, values above the ischaemic thresholds. These patients would not be expected to have symptomatic improvement with antianginal therapy or percutaneous coronary intervention (PCI) and including them could have biased the results.